The American Society of Clinical Oncology has released a conceptual framework for assessing the value of new cancer therapies based on treatment benefits, toxicities, and costs.
Developed by the ASCO Value in Cancer Care Task Force, the framework will ultimately serve as the basis for user-friendly, standardized tools that physicians can use with their patients to discuss the relative value of new cancer therapies as compared with established treatments.
ASCO is soliciting comments from all interested stakeholders on the value framework through August 21, 2015. Comments will inform the evolution of the value framework, which will be modified in response to feedback and updated as new data are developed about the utility and impact of new treatments in different clinical scenarios.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.